Ads
related to: il-17a- Dosing And Administration
Explore The Dosing And Admin Guide
For Your Potential Patients.
- Discover MOA Information
Learn About The Mechanism Of Action
And Discover How Treatment Works.
- View Clinical Results
Review Clinical Results, The Study
Design, And Actual Patient Photos.
- Safety And Efficacy
See The Clinical Results Safety
Profile. Read About Adverse Events.
- Dosing And Administration
Search results
Results From The WOW.Com Content Network
IL-17A, often referred to as IL-17, was originally discovered at transcriptional level by Rouvier et al. in 1993 from a rodent T-cell hybridoma, derived from the fusion of a mouse cytotoxic T cell clone and a rat T cell lymphoma. [5] Human and mouse IL-17A were cloned a few years later by Yao [7] and Kennedy. [8]
Among IL-17 family members, the IL-17F isoforms 1 and 2 (ML-1) have the highest sequence homology with IL-17A (55 and 40%, respectively). They follow by IL-17B, which has 29% similarity to IL-17A, IL-17D (25%), IL-17C (23%), and IL-17E (17%). In mammals, the sequences of these cytokines are highly conserved. For instance, the sequence homology ...
Interleukin-17 receptor (IL-17R) is a cytokine receptor which belongs to new subfamily of receptors binding proinflammatory cytokine interleukin 17A, a member of IL-17 family ligands produced by T helper 17 cells (Th17). [2]
Interleukin 17A (IL17A)is a proinflammatory cytokine secreted by activated T-lymphocytes. It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into neutrophils. The protein encoded by this gene (interleukin 17A receptor; IL17RA) is a ubiquitous type I membrane glycoprotein that binds with low affinity to ...
IL-17A specifically targets keratinocytes and is the major cytokine causing pathogenesis of skin psoriasis. [18] In addition, IL-17A is also expressed to an increasing extent in patients with inflammatory bowel disease. [19] ILC 3 may play a role already in the prenatal setting of the body's resistance to infections.
The effector cytokines mediated by this signalization are IL-17A, IL-4 and IL-6. IL-18 with IL-12, which is a STAT4 activator, have similar effects on Th1 cells by up-regulating expression of IL-18R1 receptor and T-bet. [38] [47]